Advate leading hemophilia treatment

Takeda Advate/Adynovate ranks first in the non-antibody category with sales of 26.2 billion won

JW Pharmaceutical leads the Hemlibra antibody market

Novoseven RT · Faiva, 5.4 billion won · 3.6 billion, GreenMono, 6.5 billion won

In the field of hemophilia non-antibody and antibody treatment, Takeda Korea Pharmaceutical and JW Pharmaceutical are gaining attention as they are strengthening their positions.

 

Korea Takeda Pharmaceutical's 'Advate/Adynovate', and JW Pharmaceutical's Hemlibra's sales last year were 26.2 billion won and 7.6 billion won, respectively, ranking first in related markets.

 

Of particular note is that the hemophilia antibody treatment market is fluctuating in line with the launch of Hemlibra in 2020.

 

Due to the emergence of strong competing products, the external expansion of traditional powerhouses Novoseven RT and Faiva is drawing a steep downward curve.

 

Novoseven RT·Faiva's sales from 2018 to 2022 show a decreasing trend from '19.5 billion - 5.4 billion won' to '6.1 billion - 3.6 billion won'.

 

In the non-antibody treatment market, six domestic and foreign pharmaceutical companies, including GC Green Cross, Pfizer Korea, Sanofi, and Bayer Korea, are competing fiercely with Takeda at the forefront.

 

Based on the sum of pharmaceutical product lines, Takeda's 'Advate/Adynovate -19.4 billion won/6.7 billion won' and GC Pharma's GreenMono/Greengene F -6.5 billion won/2.7 billion won' ranked first and second, respectively.

 

Pfizer's Xyntha Solofuse, Sanofi's Eloctate, and Bayer's Kogenate FS achieved 5.1 billion won, 3 billion won, and 1.8 billion won last year.

 

The newly released CSL Bering Korea Afstyla in 2021 showed a performance of 40 million won in the first year and about 100 million won last year.

 

The peculiarity is that except for Adynovate and Eloctate, the performance of most non-antibody treatment products is showing a downward trend, and the market also decreased by nearly 5 billion won last year compared to 50 billion won in 2018, five years ago.

 

The antibody treatment market also recorded a sales peak of 25.7 billion won in 2018, followed by a 35% decline with sales worth 16.7 billion won in 2022.

 

Hemophilia is largely divided into hemophilia A (factor VIII deficiency), hemophilia B (factor IX deficiency, also known as 'Christmas disease'), hemophilia C (factor XI deficiency), para hemophilia (factor V deficiency), and pseudo hemophilia.

 

(pseudo hemophilia) or von Willebrand disease (von Willebrand factor deficiency).

 

The incidence of hemophilia A patient is about 1 in 5,000 to 10,000 normal-born males, and hemophilia B is about one-fifth of this.

 

Von Willebrand disease occurs in both men and women and occurs in about 1 in 1000 cases.

 

It is estimated that there are 600,000 hemophilia patients worldwide, and about 12% of all hemophilia patients are hemophilia B patients.

 

In Korea, the number of patients with hemophilia A is the highest at 2,000, followed by 400 patients with hemophilia B, 100 patients with von Willebrand disease, and 20 patients with hemophilia C.